Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBIT: 2010-2024

Historic EBIT for Whitehawk Therapeutics (WHWK) over the last 13 years, with Dec 2024 value amounting to -$67.5 million.

  • Whitehawk Therapeutics' EBIT fell 45.72% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.5 million, marking a year-over-year decrease of 63.78%. This contributed to the annual value of -$67.5 million for FY2024, which is 6.22% up from last year.
  • As of FY2024, Whitehawk Therapeutics' EBIT stood at -$67.5 million, which was up 6.22% from -$71.9 million recorded in FY2023.
  • Over the past 5 years, Whitehawk Therapeutics' EBIT peaked at -$2.5 million during FY2020, and registered a low of -$111.2 million during FY2021.
  • For the 3-year period, Whitehawk Therapeutics' EBIT averaged around -$67.4 million, with its median value being -$67.5 million (2024).
  • Per our database at Business Quant, Whitehawk Therapeutics' EBIT skyrocketed by 89.57% in 2020 and then slumped by 4,263.16% in 2021.
  • Whitehawk Therapeutics' EBIT (Yearly) stood at -$2.5 million in 2020, then plummeted by 4,263.16% to -$111.2 million in 2021, then soared by 43.64% to -$62.7 million in 2022, then dropped by 14.76% to -$71.9 million in 2023, then rose by 6.22% to -$67.5 million in 2024.